Actimed Therapeutics Secures Significant New Patent, Extending IP Coverage of its Lead Compound for Use in Key Indication
London, UK – 4 May 2022: Actimed Therapeutics Ltd, a clinical
stage company focused on bringing innovation to the treatment of muscle
wasting disorders, today announced the grant of a new UK Patent (GB
2593902 B) covering new salts of S-pindolol for use in the treatment or
prevention of cachexia with an expiry date in 2040. An international
patent application has also been filed under the Patent Cooperation
Treaty (PCT) and was published in October 2021, which seeks to extend
patent protection for new S-pindolol salts to all relevant major
international markets out to 2041.
More info >> |